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Abstract
Background: Hepatitis B (HBV) and C (HCV) are important causes of morbidity and mortality in people living with
human immunodeficiency virus (HIV). The burden of these co-infections in sub-Saharan Africa is still unclear. We
estimated the prevalence of the hepatitis B surface antigen (HBsAg) and hepatitis C antibody (HCVAb) among
HIV-infected individuals in Rwanda and identified factors associated with infection.
Methods: Between January 2016 and June 2016, we performed systematic screening for HBsAg and HCVAb among
HIV-positive individuals enrolled at public and private HIV facilities across Rwanda. Results were analyzed to
determine marker prevalence and variability by demographic factors.
Results: Overall, among 117,258 individuals tested, the prevalence of HBsAg and HCVAb was 4.3% (95% confidence
interval [CI] (4.2–4.4) and 4.6% (95% CI 4.5–4.7) respectively; 182 (0.2%) HIV+ individuals were co-infected with
HBsAg and HCVAb. Prevalence was higher in males (HBsAg, 5.4% [5.1–5.6] vs. 3.7% [3.5–3.8]; HCVAb, 5.0% [4.8–5.2]
vs. 4.4% [4.3–4.6]) and increased with age; HCVAb prevalence was significantly higher in people aged ≥65 years
(17.8% [16.4–19.2]). Prevalence varied geographically.
Conclusion: HBV and HCV co-infections are common among HIV-infected individuals in Rwanda. It is important
that viral hepatitis prevention and treatment activities are scaled-up to control further transmission and reduce the
burden in this population. Particular efforts should be made to conduct targeted screening of males and the older
population. Further assessment is required to determine rates of HBV and HCV chronicity among HIV-infected
individuals and identify effective strategies to link individuals to care and treatment.
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Background
Viral hepatitis has emerged as an important public
health issue globally, characterised by high prevalence, a
high burden of morbidity and mortality, and suboptimal
diagnosis and management approaches [1, 2].
Viral hepatitis disproportionately affects persons living
with human immunodeficiency virus (HIV) [3, 4]. While
varying in their transmission efficiency, HIV, hepatitis B
(HBV), and hepatitis C (HCV) share common routes of
transmission, and as such, prevalence is generally higher
in HIV-infected individuals [3–5]. To compound this,
HIV infection accelerates the natural course of HBV and
HCV, promoting faster progression to chronicity, liver
fibrosis, and malignancy [4, 6, 7]. As antiretroviral
therapy (ART) programmes have matured and people
with HIV survive longer, viral hepatitis has become a
major cause of death in HIV-infected individuals [8].
Sub-Saharan Africa (SSA) has the highest burden of
infectious diseases and remains the epicentre of the
global HIV epidemic [9, 10]. Despite this, epidemiological
data for HBV and HCV are lacking due to limited diagnos-
tic capacity and a lack of prioritisation in public health
programmes. Available data suggest widely variable rates
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of HBV and HCV infection in HIV-infected populations
across SSA. In one meta-analysis, HIV/HBV frequency in
SSA varied from 0% to 28.4% (median 7.8%) [11]. Two re-
cent systematic reviews suggest an overall HCV preva-
lence of 3% among people living with HIV in SSA with
significant regional variations (0–55.9%) [3, 12].
Data from Rwanda is limited. Among 402 HIV-
infected, ART naïve individuals recruited from a major
Kigali-based urban healthcare facility, a 5.2% hepatitis B
surface antigen (HBsAg) and a 5.7% hepatitis C antibody
(HCVAb) prevalence were reported [13]. The HBsAg
and HCVAb prevalence were 2.4% and 4.9%, respect-
ively, in 82 samples retrospectively analysed from HIV-
positive pregnant women in 2004 [14]. A systematic
review estimated the prevalence of HCVAb in persons liv-
ing with HIV was estimated to be less than 3% in Rwanda
[3]. Given the paucity of epidemiological data from robust
studies, there is a need for nationally representative esti-
mates to ascertain the scope of the viral hepatitis burden
among HIV-positive individuals in Rwanda.
Advances in prevention and treatment have facilitated
the development of public health programmes to control
viral hepatitis in resource limited settings [15, 16].
Rwanda has been one of the first countries in SSA to es-
tablish a viral hepatitis control programme. Initiated in
2012 and building on the existing HIV infrastructure,
the programme was intensified in 2015 with the arrival
of new efficacious treatments for HCV [17]. As part of
routine programme implementation, an initiative to
screen all HIV-positive individuals enrolled into care for
key markers for HBV and HCV was implemented from
January to June 2016, reaching approximately 120,000
HIV-infected individuals nationwide.
The present study set out to characterise the preva-
lence and characteristics of HBsAg and HCVAb in HIV-
positive individuals in Rwanda using data collected
through this screening programme. Our data provide a
picture of HBV and HCV co-infection with HIV in a set-
ting where resources for screening, diagnosis, and treat-
ment are limited. Findings will be fundamental for
informing future policy and decision-making in Rwanda.
Methods
Study objectives
The primary objective of this study was to quantify the
prevalence of HBsAg and HCVAb in HIV-positive indi-
viduals enrolled into care using data collected during a
national screening activity. Secondary objectives were to
analyse data by subgroups.
Data collection
Data were obtained from the nationally representative
electronic database compiled throughout the screening
activity conducted between January and June 2016. The
programme targeted all individuals with HIV nation-
wide, enrolling individuals at all public and private
health facilities providing HIV services across Rwanda
(approximately 500 facilities). Screening was offered
free-of-charge to all HIV-positive individuals enrolled in
care at a routine appointment, regardless of ART status.
HIV-positive individuals are followed up monthly at
health facilities and as such, all eligible individuals had
the opportunity to undergo screening during the imple-
mentation period. All HIV-positive individuals screened
were included in the database which captures demo-
graphic data, HIV infection and disease characteristics,
and HBV and HCV clinical test results.
In brief, testing procedures were as follows: individuals
were invited for screening during a routine HIV appoint-
ment, specimens were collected at the site of enrolment,
and samples transported to a testing facility. Testing was
performed at 13 sites across Rwanda using Murex
enzyme-linked immunosorbent assays (ELISA) for HBsAg
(version 3.0) and HCVAb (version 4.0; DiaSorin S.p.A,
Italy). All testing was supervised by a team of laboratory
technicians from the National Reference Laboratory.
The database was de-identified for the present study
and no persons involved in the analysis of data were able
to access the linked database. For comparison, aggregate
population data for HIV-infected individuals were ob-
tained from the Rwanda national HIV health record sys-
tem (TRACnet) and were correct as of June 2016.
Statistical methods & data analysis
Sample weighting was applied in all analyses to ensure re-
sults were nationally representative of people with HIV
enrolled into care in Rwanda. The post-stratification
weights were calculated using known age, gender, and
ART distributions. All continuous variables were cate-
gorised for analysis based on appropriate thresholds.
Descriptive statistics were performed for all variables.
National prevalence estimates for HBV (HBsAg) and
HCV (HCVAb) were calculated and presented with the
corresponding 95% confidence intervals (95% CIs).
HBsAg and HCVAb prevalence by demographic and
HIV characteristics were determined; bivariate associa-
tions were tested using Pearson’s chi-square tests. All
analyses were performed using Stata software (version
12.0; StataCorp, Texas, USA).
Ethics
The routinely collected programme data analysed for
this study are maintained by the Rwanda Biomedical
Centre (RBC), Division of HIV/AIDS, STIs and Other
Blood Borne Infections; the ethical procedures for the
collection of these data are governed by the Medical
Research Council of Rwanda. Secondary analyses of
routinely collected data are exempt by the Rwanda
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Ethics Committee for routine program implementation
activities conducted by the RBC, as was the case in this
analysis.
Results
Testing coverage and population characteristics
A total of 117,258 HIV-positive individuals were
screened between January and June 2016 and were in-
cluded in the present analysis. This corresponds to a
coverage level of 64.9% of the total HIV population
enrolled to care at facilities across Rwanda. The charac-
teristics of the screened population did not differ signifi-
cantly from the overall HIV-positive population enrolled
to care.
Table 1 describes the socio-demographic and HIV
characteristics of the included individuals. The majority
of the population were female (65.1%), aged 35–54 years
(56.0%), and lived in rural areas (75.0%). Most individ-
uals were enrolled at the health centre or clinic level
(84.3%); 15.7% were enrolled at the tertiary hospital
level, inclusive of district, provincial, and referral
hospitals. Over 90% of individuals were on ART at the
time of screening.
Prevalence
The overall HBsAg and HCVAb prevalence in the HIV-
infected population and the prevalence by socio-
demographic and HIV characteristics are shown in Table 1.
HBV prevalence
In total, HBsAg result were available for 114,040/
117,258 (97.3%) individuals included in the database.
Overall, 4876/114,040 individuals were HBsAg positive.
The unadjusted and adjusted prevalence of HBsAg were
equal at 4.3% (95% CI 4.2–4.4%). Prevalence was signifi-
cantly higher in males compared with females (5.4%
[95% CI 5.1–5.6%] vs. 3.7% [95% CI 3.5–3.8%]). Preva-
lence varied by age group and was lowest in individuals
less than 15 years of age (2.1% [95% CI 1.7–2.6%]).
HBsAg prevalence was slightly higher at hospital enrol-
ment compared with enrolment at primary care level
(health centres and clinics). By geographical region,
prevalence was highest in the Eastern province (5.5%
[95% CI 5.2–5.8%]) and in the City of Kigali (5.0% [95%
CI 4.7–5.3%]); prevalence was significantly higher in
urban areas compared with rural areas (4.9% [95% CI
4.7–5.2%] vs. 4.0% [95% CI 3.9–4.2%]). Prevalence by
district is shown in (Fig. 1); prevalence varied from
10.7% (Bugesera) down to 2.1% (Ngororero).
HCV prevalence
In total, HCVAb results were available for 116,868/
117,258 (99.7%) individuals included on the database.
For HCVAb, 5470/116,868 individuals were found to be
positive. The unadjusted prevalence was 4.7% (95% CI
4.5–4.8%) and the adjusted prevalence was 4.6% (95% CI
4.5–4.7%). Like HBsAg, prevalence was higher in males
than females (5.0% [95% CI 4.8–5.2%] vs. 4.4% [4.3–4.6%]).
Prevalence increased with age, and was significantly higher
in individuals aged 55–64 (8.8% [95% CI 8.3–9.3%]) and
those aged 65 or over (17.8% [95% CI 16.4–19.2%]).
Prevalence was slightly higher at hospitals compared with
primary care facilities (5.0% [95% CI 4.7–5.3%] vs. 4.5%
[95% CI 4.4–4.7%]). HCVAb prevalence was highest in the
Southern (5.9% [95% CI 5.6–6.2%]) and Eastern (5.2% [95%
CI 4.9–5.5%]) provinces of Rwanda. In contrast to HBsAg
prevalence, HCVAb prevalence was higher in rural areas
(4.7% [95% CI 4.5–4.8%]) than urban areas (4.3% [95% CI
4.0–4.6]); however, this difference was not significant.
Prevalence of HCVAb by district is shown in Fig. 1;
HCVAb prevalence varied from 8.4% (Gisagara) to 2.7%
(Rutsiro) and was generally higher in districts bordering
other countries.
Co-infection
Of 117,258 individuals included in the database, 113,681
(96.9%) had results for both HBsAg and HCVAb. A total
of 182/113,681 individuals were coinfected with HBsAg
and HCVAb, corresponding to an adjusted co-infection
prevalence of 0.2% (95% CI 0.1–0.2%).
Discussion
Advances in treatment and the benefits of early
detection have validated the scale-up of viral hepatitis
screening efforts in resource-limited settings [15, 18].
Accordingly, a national programme was recently con-
ducted in Rwanda to screen all persons with HIV for key
HBV and HCV markers. The high screening uptake,
reaching almost 120,000 individuals, demonstrates that
large regional or national screening programmes for
viral hepatitis are feasible among HIV population in
resource-limited settings. Given the limited resources
available for population screening efforts, the present
study aimed to analyse the results to contribute towards
the understanding of the viral hepatitis co-infection bur-
den in Rwanda and to guide prioritisation for testing of
key at-risk and geographic populations.
Our study estimates the prevalence of HBsAg among
HIV-infected individuals to be 4.3%. This is consistent
with other studies conducted in Rwanda and should be
considered a robust estimate given the large sample size
[13, 14]. Due to the cross-sectional nature of this study,
we were unable to verify the persistence of HBsAg over
time; HBsAg is a good proxy for chronicity and we as-
sume that HBsAg-positivity represents chronic infection.
In accordance with the Rwanda viral hepatitis treatment
guidelines, all individuals positive for HBsAg will be
initiated on tenofovir-based ART.
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The epidemiology of HBsAg is characterised by a higher
prevalence in males, whereby males have an almost 50%
greater risk of becoming HBV infected. This finding is in
concordance with other studies conducted in SSA [19].
HIV/HBV coinfection patterns vary geographically from
2.1% up to 10.7% across the 30 districts of Rwanda.
Table 1 Baseline characteristics and prevalence of HBsAg and HCVAb by demographics and HIV characteristics
HBsAg (n = 114,040) HCVAb (n = 116,868)
Total (%) Positive (95% CI) p-valuea Total (%) Positive (95% CI) p-valuea
Overall
All 114,040 4.3 (4.2–4.4) 116,868 4.6 (4.5–4.7)
Demographic factors
Age <0.005 <0.005
< 15 4917 (4.4) 2.1 (1.7–2.6) 5062 (4.4) 1.7 (1.3–2.1)
15–24 7409 (6.6) 4.0 (3.5–4.4) 7616 (6.6) 2.1 (1.7–2.4)
25–34 21,287 (19.0) 4.2 (3.9–4.5) 21,838 (19.0) 3.1 (2.9–3.4)
35–44 34,113 (30.4) 4.8 (4.5–5.0) 34,971 (30.5) 3.8 (3.5–4.0)
45–54 28,719 (25.6) 4.5 (4.2–4.7) 29,371 (25.6) 4.7 (4.5–5.0)
55–64 12,582 (11.2) 4.0 (3.6–4.4) 12,871 (11.2) 8.8 (8.3–9.3)
≥ 65 3037 (2.7) 3.9 (3.2–4.6) 3098 (2.7) 17.8 (16.4–19.2)
Gender <0.005 <0.005
Female 74,141 (65.1) 3.7 (3.5–3.8) 75,946 (65.1) 4.4 (4.3–4.6)
Male 39,751 (34.9) 5.4 (5.1–5.6) 40,774 (34.9) 5.0 (4.8–5.2)
Enrolment facility 0.031 0.013
Health center 92,576 (84.2) 4.2 (4.0–4.3) 94,991 (84.3) 4.5 (4.4–4.7)
Hospital 17,346 (15.8) 4.5 (4.2–4.9) 17,715 (15.7) 5.0 (4.7–5.3)
Geographical factors
Province <0.005 <0.005
Kigali 19,135 (16.8) 5.0 (4.7–5.3) 19,413 (16.6) 4.0 (3.7–4.2)
East 23,404 (20.5) 5.5 (5.2–5.8) 25,874 (22.1) 5.2 (4.9–5.5)
North 16,094 (14.1) 4.2 (3.9–4.6) 16,114 (13.8) 4.2 (3.9–4.6)
South 27,368 (24.0) 3.6 (3.4–3.9) 27,367 (23.4) 5.9 (5.6–6.2)
West 28,027 (24.6) 3.5 (3.3–3.7) 28,086 (24.0) 3.5 (3.3–3.8)
Residenceb <0.005 0.013
Rural 73,820 (74.7) 4.0 (3.9–4.2) 76,070 (75.1) 4.7 (4.5–4.8)
Urban 24,975 (25.3) 4.9 (4.7–5.2) 25,198 (24.9) 4.3 (4.0–4.6)
HIV characteristics
ART category 0.214 <0.005
On ART 98,974 (91.6) 4.3 (4.2–4.5) 101,510 (91.5) 4.4 (4.3–4.5)
Pre ART 9119 (8.4) 4.1 (3.6–4.5) 9381 (8.5) 6.6 (6.1–7.1)
CD4 countb <0.005 <0.005
≤ 500 34,698 (41.2) 4.9 (4.7–5.1) 35,339 (41.2) 5.0 (4.8–5.3)
> 500 49,469 (58.8) 3.7 (3.6–3.9) 50,497 (58.8) 4.4 (4.2–4.6)
HIV viral loadb <0.005 0.433
≤ 1000 66,272 (95.1) 3.9 (3.7–4.1) 67,424 (95.1) 4.3 (4.1–4.5)
> 1000 3406 (4.9) 5.5 (4.6–6.4) 3486 (4.9) 4.6 (3.8–5.4)
Results are proportion positive (95% confidence interval); Sampling weights have been applied
aReported are Chi-Square p-values; statistically significant p-values are in bold (p < 0.05)
bMissing responses ≥10%
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Of note, the HBsAg prevalence is lowest in children
below 15 years, motivated by the roll-out of HBV vaccin-
ation activities since 2002. Despite this decrease, our
findings indicate that strengthening of vaccination
activities is required. At present, the HBV birth-dose
vaccination, administered within 24 h of birth is not
implemented and should be considered as a strategy to
reduce perinatal transmission [18]. Further, HBV vaccin-
ation in HIV-positive populations may provide a moder-
ately lower response rate than in the general population,
and as such, implementing polices with 1) specific
immunisation algorithms for HIV-infected/exposed chil-
dren and 2) vaccine response monitoring should be ex-
plored [19–21].
We found an HCVAb seroprevalence of 4.6% among
HIV-infected individuals, marginally lower than that ob-
served in previous studies (4.9–5.6%) [13, 14]. Consistent
with findings from other SSA populations, HCVAb epi-
demiology is characterised by a higher prevalence in
males, and by an increasing prevalence with the increase
in age [22–25]. Cumulative exposure may explain the as-
sociation between HCVAb prevalence and older age.
However, given the strikingly higher prevalence in indi-
viduals over 55 years, it is likely the association is im-
pacted by a cohort effect of patients infected many years
ago. Our findings indicate that one-time screening of in-
dividuals aged over 55 should be recommended. Birth-
cohort screening is in practice or has been evaluated in
various other settings and has largely been identified as
a cost-effective initiative [26–29].
HCVAb prevalence varies geographically from 2.7% to
8.4% across Rwanda’s 30 districts and key districts in
which mass screening activities should be implemented
have been identified. Efforts should also be made to scale
up screening in border districts where HCVAb preva-
lence in the HIV population has been observed to be
higher than average.
The main limitation of the present study is the absence
of confirmation of chronic HCV infection with HCV RNA
testing. Several studies have suggested that HCV serology
is prone to false-positive results, especially in HIV-infected
patients in SSA where the proportion of individuals con-
firmed by detection of HCV RNA after a positive HCVAb
test is lower than other parts of the world [12, 30, 31].
Further, HCVAb presence includes those with resolved
infection and as such does not necessarily confer active
infection. There is conflicting evidence surrounding
viremia rate across SSA, suggesting the possibility of local-
ised outbreaks and the need for specific data to understand
endemicity [12, 30, 32–34]. Molecular characterisation is
required to determine the prevalence of chronic HCV and
to accurately reflect current needs for HCV treatment in
Rwanda. Despite this, the prevalence of HCVAb is still
meaningful, filling knowledge gaps on individuals more
likely to become infected with HCV.
This study was further limited by its retrospective
nature. Ideally, this would have been an opportunity to
collate risk factors for viral hepatitis infection in
Rwanda. The authors decided against a risk factor re-
gression analysis as many key risk factors for infection
were not collected and the model would have been of
limited application.
Conclusions
This study adds to the understanding of viral hepatitis
among HIV-infected individuals in Rwanda. The expanded
Fig. 1 Prevalence of a HBsAg and b HCVAb by District, Rwanda
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viral hepatitis testing activity has achieved early diagnosis
of individuals that will facilitate linkage to further testing
and care, reducing hepatitis-related morbidity and curbing
onward disease transmission. The findings presented
should be used to inform policy and targeted screening
activities, and should be extrapolated beyond the HIV posi-
tive population. Additional studies should be performed in
HIV positive and HIV negative individuals to fill the
remaining gaps in the epidemiological profile of these
diseases and to determine risk factors for infection. In par-
ticular, molecular characterisation and detection of other
markers should be conducted to determine the exact
prevalence of viral hepatitis in this population.
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